SEARCH

SEARCH BY CITATION

References

  • Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B., de Haes, J.C., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P.B., Schraub, S., Sneeuw, K., Sullivan, M. & Takeda, F. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365376.
  • Baffert, F., Regnier, C.H., De Pover, A., Pissot-Soldermann, C., Tavares, G.A., Blasco, F., Brueggen, J., Chene, P., Drueckes, P., Erdmann, D., Furet, P., Gerspacher, M., Lang, M., Ledieu, D., Nolan, L., Ruetz, S., Trappe, J., Vangrevelinghe, E., Wartmann, M., Wyder, L., Hofmann, F. & Radimerski, T. (2010) Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. Molecular Cancer Therapeutics, 9, 19451955.
  • Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S. & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761770.
  • Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 48294833.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Brucker, P.S., Yost, K., Cashy, J., Webster, K. & Cella, D. (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Evaluation and the Health Professions, 28, 192211.
  • Campbell, P.J. & Green, A.R. (2006) The myeloproliferative disorders. New England Journal of Medicine, 355, 24522466.
  • Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 28952901.
  • Fridman, J., Nussenzveig, R. & Liu, P. (2007) Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders. Blood (ASH Annual Meeting Abstracts), 110, Abstract 3538.
  • Fridman, J.S., Scherle, P.A., Collins, R., Burn, T.C., Li, Y., Li, J., Covington, M.B., Thomas, B., Collier, P., Favata, M.F., Wen, X., Shi, J., McGee, R., Haley, P.J., Shepard, S., Rodgers, J.D., Yeleswaram, S., Hollis, G., Newton, R.C., Metcalf, B., Friedman, S.M. & Vaddi, K. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. Journal of Immunology, 184, 52985307.
  • Gale, R.P., Barosi, G., Barbui, T., Cervantes, F., Dohner, K., Dupriez, B., Gupta, V., Harrison, C., Hoffman, R., Kiladjian, J.J., Mesa, R., Mc Mullin, M.F., Passamonti, F., Ribrag, V., Roboz, G., Saglio, G., Vannucchi, A. & Verstovsek, S. (2011) What are RBC-transfusion-dependence and -independence? Leukemia Research, 35, 811.
  • Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelmann, N., Jones, A.V., Zoi, K., Reiter, A., Duncombe, A., Villani, L., Bosi, A., Barosi, G., Cross, N.C. & Vannucchi, A.M. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 118, 52275234.
  • Harrison, C.N., Kiladjian, J.J., Gisslinger, H., Niederwieser, D., Passamonti, F., Waltzman, R.J., Hollaender, N., Hunter, D.S., Levy, R.S., Knoops, L., Cervantes, F., Vannucchi, A.N., Barbui, T. & Barosi, G. (2011) Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: an Analysis of Spleen Response in the COMFORT-II Study. Blood (ASH Annual Meeting Abstracts), 118, Abstract 279.
  • Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787798.
  • Hart, S., Goh, K.C., Novotny-Diermayr, V., Hu, C.Y., Hentze, H., Tan, Y.C., Madan, B., Amalini, C., Loh, Y.K., Ong, L.C., William, A.D., Lee, A., Poulsen, A., Jayaraman, R., Ong, K.H., Ethirajulu, K., Dymock, B.W. & Wood, J.W. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia, 25, 17511759.
  • Hernandez-Boluda, J.C., Alvarez-Larran, A., Gomez, M., Angona, A., Amat, P., Bellosillo, B., Martinez-Aviles, L., Navarro, B., Teruel, A., Martinez-Ruiz, F. & Besses, C. (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British Journal of Haematology, 152, 8188.
  • Heuck, G. (1879) Zwei Fälle von Leukämie mit eigenthümlichem Blut-resp Knochenmarksbefund. Virchows Archiv (Pathological Anatomy), 78, 475.
  • Hexner, E.O., Serdikoff, C., Jan, M., Swider, C.R., Robinson, C., Yang, S., Angeles, T., Emerson, S.G., Carroll, M., Ruggeri, B. & Dobrzanski, P. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood, 111, 56635671.
  • Hexner, E., Goldberg, J.D., Prchal, J.T., Demakos, E.P., Swierczek, S., Weinberg, R.S., Tripodi, J., Najfeld, V., Carroll, M., Marchioli, R., Silverman, L.R. & Hoffman, R. (2009) A multicenter, open label Phase I/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium. Blood (ASH Annual Meeting Abstracts), 114, Abstract 754.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • Jiang, J.K., Ghoreschi, K., Deflorian, F., Chen, Z., Perreira, M., Pesu, M., Smith, J., Nguyen, D.T., Liu, E.H., Leister, W., Costanzi, S., O'Shea, J.J. & Thomas, C.J. (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). Journal of Medicinal Chemistry, 51, 80128018.
  • Kiladjian, J.J., Lesteven, E., Massé, A., Cassinat, B., Turlure, P., Bellucci, S. & Delhommeau, F. (2011) Impact of Peg-interferon-alpha-2A therapy on the evolution of JAk2 and TET2 mutated clones in polycythemia vera. Haematologica, 96(Suppl. 2), A1062A1445.
  • Knapper, S., Burnett, A.K., Littlewood, T., Kell, W.J., Agrawal, S., Chopra, R., Clark, R., Levis, M.J. & Small, D. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 108, 32623270.
  • Komrokji, R.S., Wadleigh, M., Seymour, J.F., Roberts, A.W., To, L.B., Zhu, H.J. & Mesa, R.A. (2011) Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. Blood (ASH Annual Meeting Abstracts), 118, 282.
  • Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 17791790.
  • Kroger, N., Alchalby, H., Klyuchnikov, E., Badbaran, A., Hildebrandt, Y., Ayuk, F., Bacher, U., Bock, O., Kvasnicka, M., Fehse, B. & Zander, A. (2009) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood, 113, 18661868.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Liu, P.C., Caulder, E., Li, J., Waeltz, P., Margulis, A., Wynn, R., Becker-Pasha, M., Li, Y., Crowgey, E., Hollis, G., Haley, P., Sparks, R.B., Combs, A.P., Rodgers, J.D., Burn, T.C., Vaddi, K. & Fridman, J.S. (2009) Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clinical Cancer Research, 15, 68916900.
  • Ma, L., Zhao, B., Walgren, R., Clayton, J.A., Blosser, W.D., Burkholder, T.P. & Smith, M.C. (2010) Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models. Blood (ASH Annual Meeting Abstracts), 116, 4087.
  • Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A. & Tefferi, A. (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer, 109, 6876.
  • Mesa, R.A., Pardanani, A.D., Hussein, K., Wu, W., Schwager, S., Litzow, M.R., Hogan, W.J. & Tefferi, A. (2010) Phase1/-2 study of Pomalidomide in myelofibrosis. American Journal of Hematology, 85, 129130.
  • Mesa, R., Kantarjian, H. & Shields, A. (2011) Results using the Modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0) in COMFORT-I: a randomized, double-blind phase III trial of JAK1/2 inhibitor ruxolitinib vs. placebo in myelofibrosis (MF). Haematologica, 96(6, Suppl. 2), Abstract 0912.
  • Moliterno, A.R., Hexner, E., Roboz, G.J., Carroll, M., Luger, S., Mascarenhas, J., Hoffman, R. & Bensen-Kennedy, D.M. (2009) An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: update of 39 Enrolled Patients. Blood (ASH Annual Meeting Abstracts), 114, 753.
  • Oh, S.T., Simonds, E.F., Jones, C., Hale, M.B., Goltsev, Y., Gibbs, Jr, K.D., Merker, J.D., Zehnder, J.L., Nolan, G.P. & Gotlib, J. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood, 116, 988992.
  • Paquette, R., Sokal, L., Shah, N.P., Silver, R.T., List, A.F., Clary, D.O., Bui, L.A. & Talpaz, M. (2008) A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood (ASH Annual Meeting Abstracts), 112, Abstract 2810.
  • Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. & Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 34723476.
  • Pardanani, A., Gotlib, J., Jamieson, C., Cortes, J., Talpaz, M., Stone, R., Silverman, M.H., Shorr, J., Gilliland, D.G. & Tefferi, A. (2009a) A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood (ASH Annual Meeting Abstracts), 114, Abstract 755.
  • Pardanani, A., Lasho, T., Smith, G., Burns, C.J., Fantino, E. & Tefferi, A. (2009b) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 23, 14411445.
  • Pardanani, A., Gotlib, J.R., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R.M., Silverman, M.H., Gilliland, D.G., Shorr, J. & Tefferi, A. (2011a) Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 29, 789796.
  • Pardanani, A., Gotlib, J., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R., Gao, G., Zhang, J., Neumann, F. & Tefferi, A. (2011b) SAR302503: interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis. Blood (ASH Annual Meeting Abstracts), 118, 3838.
  • Pardanani, A., Gotlib, J., Gupta, V., Roberts, A.W., Wadleigh, M., Sirhan, S., Litzow, M.R., Hogan, W.J., Begna, K., Smith, G., Bavisotto, L.M., Kowalski, M. & Tefferi, A. (2011c) An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis. Blood (ASH Annual Meeting Abstracts), 118, 3849.
  • Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., Vanin, E.F., Bodner, S., Colamonici, O.R., van Deursen, J.M., Grosveld, G. & Ihle, J.N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell, 93, 385395.
  • Quintas-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P.A., Caulder, E., Wen, X., Li, Y., Waeltz, P., Rupar, M., Burn, T., Lo, Y., Kelley, J., Covington, M., Shepard, S., Rodgers, J.D., Haley, P., Kantarjian, H., Fridman, J.S. & Verstovsek, S. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 115, 31093117.
  • Saharinen, P. & Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. Journal of Biological Chemistry, 277, 4795447963.
  • Samuelson, S., Sandmaier, B.M., Heslop, H.E., Popat, U., Carrum, G., Champlin, R.E., Storb, R., Prchal, J.T., Gooley, T.A. & Deeg, H.J. (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. British Journal of Haematology, 153, 7682.
  • Santos, F.P., Kantarjian, H.M., Jain, N., Manshouri, T., Thomas, D.A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J. & Verstovsek, S. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 115, 11311136.
  • Scherber, R., Dueck, A.C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Harrison, C.N., Radia, D. & Mesa, R.A. (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international Prospective Validation and Reliability Trial in 402 patients. Blood, 118, 401408.
  • Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459468.
  • Shah, N., Olszynski, P., Sokal, L., Verstovsek, S., Hoffman, R., List, A.F., Cortes, J., Kantarjian, H.M., Gilliland, D.G., Clary, D.O., Bui, L.A. & Wadleigh, M. (2008) A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood, 112, Abstract 98.
  • Shide, K., Kameda, T., Markovtsov, V., Matsunaga, T., Shimoda, H., Hidaka, T., Katayose, K., Kubuki, Y., Bhamidipati, S., Park, G., Torneros, A., Duan, M., Hitoshi, Y. & Shimoda, K. (2009) Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2 V617F-Induced Murine MPD Model. Blood (ASH Annual Meeting Abstracts), 11, Abstract 3897.
  • Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, Jr, L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. & Kantarjian, H. (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108, 14971503.
  • Tefferi, A., Kantarjian, H.M. & Pardanani, A.D. (2008) The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2. Blood (ASH Annual Meeting Abstracts), 112, Abstract 2804.
  • Tefferi, A., Litzow, M.R. & Pardanani, A. (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. New England Journal of Medicine, 365, 14551457.
  • Tyner, J.W., Bumm, T.G., Deininger, J., Wood, L., Aichberger, K.J., Loriaux, M.M., Druker, B.J., Burns, C.J., Fantino, E. & Deininger, M.W. (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115, 52325240.
  • Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 17231735.
  • Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937951.
  • Verstovsek, S., Odenike, O., Scott, B., Estrov, Z., Cortes, J., Thomas, D.A., Wood, J., Ethirajulu, K., Lowe, A., Zhu, H.J., Kantarjian, H. & Deeg, H.J. (2009) Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis. Blood, 114, Abstract 3905.
  • Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R. & Tefferi, A. (2010a) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine, 363, 11171127.
  • Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P.J., Levy, R., Bradley, E., Garrett, W., Vaddi, K., Contel, N., Sandor, V., . Huber, R.M., Schacter, L.P., Rumi, E., Gattoni, E., Antonioli, E., Pieri, L., Cazzola, M., Kantarjian, H., Barbui, T. & Vannucchi, A.M. (2010b) Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood (ASH Annual Meeting Abstracts), 116, 313.
  • Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J., Deininger, M.W., Miller, C.W., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V.A. & Kantarjian, H.M. (2011a) Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: results From COMFORT-I. Blood (ASH Annual Meeting Abstracts), 118, Abstract 278.
  • Verstovsek, S., Kantarjian, H.M., Estrov, Z., Cortes, J.E., Thomas, D.A., Kadia, T., Pierce, S., Cazzola, M., Rumi, E., Morra, E., Pungolino, E., Caramazza, D. & Passamonti, F. (2011b) Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: survival Advantage of Ruxolitinib Therapy. Blood (ASH Annual Meeting Abstracts), 118, Abstract 793.
  • Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine, 366, 799807.
  • Wernig, G., Kharas, M.G., Okabe, R., Moore, S.A., Leeman, D.S., Cullen, D.E., Gozo, M., McDowell, E.P., Levine, R.L., Doukas, J., Mak, C.C., Noronha, G., Martin, M., Ko, Y.D., Lee, B.H., Soll, R.M., Tefferi, A., Hood, J.D. & Gilliland, D.G. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell, 13, 311320.
  • Wilks, A.F. (1989) Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America, 86, 16031607.
  • Wilks, A.F., Harpur, A.G., Kurban, R.R., Ralph, S.J., Zurcher, G. & Ziemiecki, A. (1991) Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Molecular and Cellular Biology, 11, 20572065.